Search clinical trials for: Anti R-IL2 Cyclosporine then Everolimus

Total 148 results

University Hospital, Brest
Novartis; Roche Pharma AG; Ministry of Health, France; Genzyme, a Sanofi Company

Completed

mTor-inhibitor (EVERolimus) Based Immunosuppressive Strategies for CNI Minimisation in OLD for Old Renal Transplantation (EVEROLD)

Renal Transplant

France
Novartis Pharmaceuticals

Completed

Efficacy and Safety of AEB071 Versus Cyclosporine in de Novo Renal Transplant Recipients

Kidney Transplantation

Belgium, Taiwan, Italy, Germany, Spain, Switzerland, Australia, Singapore, Norway, Netherlands, Colombia, Argentina, Brazil, Austria, Slovakia, France, Czech Republic
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Everolimus in Combination With Cyclosporine Microemulsion Versus Everolimus in Combination With Enteric-coated Mycophenolate Sodium (EC-MPS), in Adult Renal Transplant Patients in Maintenance.

Renal Transplantation

France
University Hospital Schleswig-Holstein
University of Kiel

Completed

Polymorphism of the Cytochrome P450-system in Renal Transplants

Function of Renal Transplant

Germany
Centre Hospitalier Universitaire, Amiens
Novartis

Unknown

Comparison of Efficacy and Safety of Treatment With a Calcineurin Inhibitor (CNI)Versus a CNI-free Treatment in Renal Transplantation (CIME) (CIME)

Kidney Failure

France
Hannover Medical School

Unknown

Studying the Effect of Changing Immunosuppression in Case of Polyoma BK Virus Infection of the Renal Transplant (BKVIRUS)

Virus Diseases | Disorder Related to Renal Transplantation | Immunosuppression Related Infectious Disease

Germany
Novartis Pharmaceuticals

Completed

Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients.

Renal Function | Liver Transplant

United States, Germany, Spain, Belgium, France, Hungary, Australia, Sweden, Italy, Canada, United Kingdom, Denmark
Mahidol University

Unknown

Efficacy and Safety of Everolimus in de Novo Kidney Transplant Recipients of ECD or AKI Donors

Transplantation of Kidney | ECD | Expanded Criteria Donor
Novartis Pharmaceuticals

Active, not recruiting

Combination of Eltrombopag With Immunosuppressive Therapy in East-Asian Patients With Severe Aplastic Anemia (REACTS)

Severe Aplastic Anemia (SAA)

Japan, Korea, Republic of, China, Taiwan
Hospices Civils de Lyon

Unknown

Ciclosporin A and Acute Myocardial Infarction

Myocardial Infarction

France
Novartis

Completed

Once-a-day Regimen With Everolimus, Low Dose Cyclosporine and Steroids in Comparison With Steroid Withdrawal or Twice a Day Regimen With Everolimus, Low Dose Cyclosporine and Steroids. (EVIDENCE)

Renal Transplantation | de Novo Kidney Transplant Recipients

Italy
University Hospital, Limoges

Completed

Pharmacokinetics of Immunosuppressive Drugs in Heart Transplant Patients (PIGREC)

Heart Transplant

France
Novartis Pharmaceuticals

Completed

Everolimus in Combination With Cyclosporine Microemulsion in de Novo Renal Transplant Recipients (EVEREST)

Transplantation Infection
University of Giessen
Novartis; Hoffmann-La Roche; Astellas Pharma Inc; Heidelberg University

Completed

Impact of Immunosuppressive Regimens on Polyomavirus-related Transplant Nephropathy

Polyomavirus Infections

Germany
Deise de Boni Monteiro de Carvalho

Unknown

Study to Evaluate the Safety and Efficacy of Switching Calcineurin Inhibitor to Everolimus After Kidney Transplantation in Adults

Immunosuppression | Kidney Transplant

Brazil
Novartis Pharmaceuticals

Completed

Efficacy, Safety and Evolution of Cardiovascular Parameters in Renal Transplant Recipients (ELEVATE)

Kidney Transplantation

Germany, Belgium, Netherlands, Australia, Austria, Italy, Spain, Thailand, Estonia, Norway, Lithuania, Turkey, Mexico, Argentina, Greece, Russian Federation, Portugal, France, India, Latvia, Romania
University of Bologna

Terminated

Shift to Everolimus (RAD) Kidney Sparing Study

Heart Transplantation | Kidney Dysfunction

Italy
Milton S. Hershey Medical Center
Novartis Pharmaceuticals

Completed

Conversion to Everolimus From Calcineurin Inhibitor With Mycophenolic Acid: Impact on Long Term Renal Function in Liver Transplantation.

Renal Failure | Immunosuppression

United States
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Everolimus in Recipients of Heart Transplants to Prevent Acute and Chronic Rejection

Graft Rejection

United Kingdom, Canada, Taiwan, United States, France, Belgium, Spain, Australia, Germany, New Zealand, Argentina, Italy, Austria, Norway, Puerto Rico
Irmandade Santa Casa de Misericórdia de Porto Alegre
Novartis

Completed

Effect of Switching to Certican® in Viremia of Hepatitis C Virus in Adult Renal Allograft Recipients (CONCERVIC)

Hepatitis C | Renal Allograft

Brazil
Novartis

Completed

Everolimus in a Cyclosporine Microemulsion-free Regimen Compared to a Low-dose Cyclosporine Microemulsion Regimen, in de Novo Kidney Transplant Patients (CERTES02)

Organ Transplantation, Renal Transplantation
Novartis Pharmaceuticals

Terminated

Comparison of CNI-based Regimen Versus CNI-free Regimen in Kidney Transplant Recipients.

Renal Transplantation

Germany
Novartis

Completed

Concentration Controlled Everolimus With Reduced Dose Cyclosporine Versus Mycophenolate Mofetil With Standard Dose Cyclosporine in de Novo Renal Transplant Adult Recipients Treated With Basiliximab and Corticosteroids

Kidney Transplantation

Japan
Novartis Pharmaceuticals

Completed

A Study Investigating the Renal Tolerability, Efficacy, and Safety of a CNI-free Versus a Standard Regimen in de Novo Heart Transplant (HTx) Recipients (MANDELA)

Heart Transplantation

Germany
Novartis Pharmaceuticals

Terminated

Study to Evaluate the Efficacy, Safety and Tolerability of Everolimus in de Novo Renal Transplant Recipients Participating in the Eurotransplant Senior Program (Senator)

Renal Transplantation

Germany
Novartis Pharmaceuticals

Completed

SOCRATES: Steroid or Cyclosporine Removal After Transplantation Using Everolimus

Renal Transplanted Recipients

Australia
Novartis Pharmaceuticals

Completed

Study Investigating a Standard Regimen in de Novo Kidney Transplant Patients Versus a Calcineurin Inhibitor (CNI)-Free Regimen and a CNI-low Dose Regimen

Kidney Transplantation

Germany, Switzerland
Novartis

Completed

Efficacy and Safety Study of Everolimus Plus Reduced Cyclosporine Versus Mycophenolic Acid Plus Cyclosporine in Kidney Transplant Recipients

Kidney Transplantation | Graft Rejection

United States
Novartis Pharmaceuticals

Completed

12 Month Athena Study: Everolimus vs. Standard Regimen in de Novo Kidney Transplant Patients (ATHENA)

Kidney Transplantation | Renal Transplantation

Germany, France
Novartis Pharmaceuticals

Completed

Evaluation of Early Conversion to Everolimus From Cyclosporine in de Novo Renal Transplant Recipients

Renal Function

Denmark, Norway, Sweden
Novartis Pharmaceuticals

Completed

SCHEDULE Follow Up Visit 5-7 yr (CRAD001ANO05)

Heart Transplantation

Denmark, Norway, Sweden
Novartis Pharmaceuticals

Completed

SCHEDULE - Scandinavian Heart Transplant Everolimus de Novo Study With Early Calcineurin Inhibitor (CNI) Avoidance (SCHEDULE)

Renal Function and Chronic Allograft Vasculopathy

Norway, Denmark, Sweden
Hospices Civils de Lyon

Withdrawn

CYclosporine A in Shockable Out-of-hospital Cardiac Arrest ResUScitation (CYRUS II)

Shockable Out of Hospital Cardiac Arrest

France
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Terminated

Cyclophosphamide, Antithymocyte Globulin, and Total-Body Irradiation in Treating Patients With Severe Aplastic Anemia Undergoing Umbilical Cord Blood Transplant

Aplastic Anemia

United States
Sohag University

Not yet recruiting

Cyclosporine Adverse Outcomes in Steroid Dependent and Frequent Relapsing Nephrotic Syndrome in Children;Single Center Study

Steroid Dependent and Frequent Relapsing Nephrotic Syndrome

Egypt
Novartis Pharmaceuticals

Completed

Pharmacodynamics, Efficacy and Safety of Basiliximab 40 or 80 mg in Combination With Ciclosporine Microemulsion or Everolimus, in Adult Low Risk de Novo Renal Transplant Recipients (IDEALE Study) (IDEALE)

Renal Transplantation

France
University of Minnesota
Novartis; Juvenile Diabetes Research Foundation; National Institutes of Health...

Completed

Anti-Thymocyte Globulin, Cyclosporine, and RAD in Islet Transplantation (NITA)

Hypoglycemia | Type 1 Diabetes Mellitus

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant

Acute Myeloid Leukemia | Hodgkin Lymphoma | Waldenstrom Macroglobulinemia | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia | Non-Hodgkin Lymphoma | Plasma Cell Myeloma | Myelodysplastic/Myeloproliferative Neoplasm | Graft Versus Host Disease | Chronic Myelogenous Leukemia, BCR-ABL1 Positive

United States, Italy
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Rabbit Antithymocyte Globulin Versus Campath-1H for Treating Severe Aplastic Anemia

Aplastic Anemia

United States
Masonic Cancer Center, University of Minnesota

Completed

Allogeneic Bone Marrow Transplant for Inherited Metabolic Disorders

Mucopolysaccharidosis | Hurler Syndrome | Sphingolipidoses | Peroxisomal Disorders | Krabbe Disease | Adrenoleukodystrophy (ALD) | Hunter Syndrome | Sly Syndrome | Fucosidosis | Aspartylglucosaminuria | Alpha Mannosidosis | Metachromatic Leukodystrophy (MLD) | Maroteaux-Lamy Syndrome

United States
Fred Hutchinson Cancer Center

Completed

Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematological Cancer Who Are Undergoing Umbilical Cord Blood Transplant

Myelodysplastic Syndrome (MDS) | Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Acute Biphenotypic Leukemia | Acute Myeloid Leukemia in Remission | Acute Lymphoblastic Leukemia in Remission | Blasts Under 5 Percent of Bone Marrow...

United States
Assistance Publique - Hôpitaux de Paris

Completed

Dose-effect Relationship of Low-dose IL-2 in Type 1 Diabetes (DF-IL2)

Type 1 Diabetes

France
Sahajanand Medical Technologies Pvt. Ltd.
Cardialysis BV

Terminated

SERIES III RUN-IN Clinical Trial: A Comparison of the Supralimus® Stent With the Xience V™ Stent

Coronary Artery Disease

India, Brazil, Saudi Arabia
Maasstad Hospital

Unknown

Comparison of the Everolimus Eluting With the Biolimus A9 Eluting Stent (COMPARE-II)

Coronary Artery Disease

Netherlands, Spain, Switzerland, Greece
Novartis Pharmaceuticals

Completed

Everolimus in de Novo Kidney Transplant Recipients (NEVERWOUND)

Kidney Transplantation

Italy
Novartis Pharmaceuticals

Completed

Progression of Renal Interstitial Fibrosis / Tubular Atrophy (IF/TA) According to Epithelial-mesenchymal Transition (EMT) and Immunosuppressive Regimen (Everolimus Based Versus CNI Based) in de Novo Renal Transplant Recipients (CERTITEM)

Renal Interstitial Fibrosis

France
Beijing Tiantan Hospital

Completed

Triamcinolone Acetonide as an Adjuvant to Pre-emptive Scalp Infiltration for Relief of Post-craniotomy Pain in Adults

Pain, Postoperative

China
Shahid Beheshti University of Medical Sciences

Completed

Comparison of Safety and Efficacy of de Novo Everolimus

Cytomegalovirus Infections

Iran, Islamic Republic of
Fred Hutchinson Cancer Center
medac GmbH

Recruiting

Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies

Acute Myeloid Leukemia | Hodgkin Lymphoma | Chronic Myelomonocytic Leukemia | Burkitt Lymphoma | Acute Lymphoblastic Leukemia | Lymphoblastic Lymphoma | Mantle Cell Lymphoma | Lymphoplasmacytic Lymphoma | Anaplastic Large Cell Lymphoma | Acute Leukemia | Myelodysplastic Syndrome | Prolymphocytic Leukemia | Refractory... and other conditions

United States
Novartis

Completed

Efficacy and Safety of Everolimus With Enteric-Coated Mycophenolate Sodium (EC-MPS) in a Cyclosporine Microemulsion-free Regimen Compared to Standard Therapy in de Novo Renal Transplant Patients

Renal Transplantation

Switzerland, Germany

Search clinical trials for: Anti R-IL2 Cyclosporine then Everolimus

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Estonia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations